Combination Therapy for the Treatment of Ocular Neovascular Disorders
The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention of a neovascular disorder.
1 - 15 . (canceled)
16 . A method for treating an ocular neovascular disorder, comprising administering to a mammal in need thereof:
(a) a PDGF antagonist, wherein the PDGF antagonist is a pegylated aptamer having the sequence of SEQ ID NO: 23; and
(b) a VEGF antagonist, wherein the VEGF antagonist is a humanized anti-VEGF antibody having a light chain variable domain comprising the sequence of SEQ ID NO: 27 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 26,
wherein the PDGF antagonist and the VEGF antagonist are administered simultaneously or within 90 days of each other, and wherein the PDGF antagonist and the VEGF antagonist are administered in an amount effective to treat the ocular neovascular disorder in the mammal, and
wherein the ocular neovascular disorder is age-related macular degeneration (AMD).
17 . The method of claim 16 , wherein the PDGF antagonist and the VEGF antagonist are administered within 10 days of each other.
18 . The method of claim 16 , wherein the PDGF antagonist and the VEGF antagonist are administered within 5 days of each other.
19 . The method of claim 16 , wherein the PDGF antagonist and the VEGF antagonist are administered within 24 hours of each other.
20 . The method of claim 16 , wherein the PDGF antagonist and the VEGF antagonist are administered simultaneously.
21 . The method of claim 16 , wherein the PDGF antagonist and VEGF antagonist are administered separately in individual dosage amounts.
22 . The method of claim 16 , wherein the PDGF antagonist and VEGF antagonist are administered together in the same composition.
23 . The method of claim 16 , wherein the age-related macular degeneration is wet-type AMD.